galavit and Lung-Neoplasms

Administration of an immunomodulator, galavit, for stage II-III non-small lung cancer along with standard therapy was followed by immunological vigor improvement by the end of the course. CD3, CD4, IgA, IgM and IgG indices were normal in more than 80% of the study group by day 51 after surgery; CD8, CD20 and HLA-DR--in more than 50%; CD16--in 45.2%. In control, by day 51, normal IgG and HLA-DR levels were reported in 60%. The remaining indices were normal in less than 50%. Our results point to immunological vigor improvement due to use of galavit. The drug is well tolerated, has neither side effects nor toxicity.

Topics: Adult; Aged; Antigens, CD20; Antigens, Neoplasm; Carcinoma, Non-Small-Cell Lung; CD3 Complex; CD4 Antigens; CD8 Antigens; Double-Blind Method; Female; HLA-DR Antigens; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunologic Factors; Luminol; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Phthalazines; Receptors, IgG